<DOC>
	<DOCNO>NCT02026063</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability orally administer telotristat etiprate .</brief_summary>
	<brief_title>Telotristat Etiprate - Expanded Treatment Patients With Carcinoid Syndrome Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Ongoing participation Phase 2 ( LX1606.1202CS , LX1606.1203CS ) Phase 3 ( LX1606.1301CS , LX1606.1303CS ) study Patients childbearing potential must agree use adequate method contraception ( defined failure rate &lt; 1 % per year ) study 12 week Followup visit . Ability willingness provide write informed consent Major protocol violation tolerability concern Phase 2 ( eg , LX1606.1202CS , LX1606.1203CS ) Phase 3 ( eg , LX1606.1301CS , LX1606.1303CS ) study Positive pregnancy test Presence clinically significant finding entry medical history , laboratory value , physical examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>